Asthma Control Questionnaire

Abstract

The Asthma Control Questionnaire (ACQ) is a widely recognized, multidimensional patient-reported outcome measure developed by Professor Elizabeth F. Juniper and colleagues in 1999 to evaluate clinical asthma control in pediatric and adult populations. Formulated to reflect international clinical management guidelines, such as those established by the Global Initiative for Asthma (GINA) and the National Institutes of Health (NIH), the standard instrument comprises seven items evaluating core manifestations of asthma impairment over the previous week. These items encompass nocturnal awakening, morning symptoms upon waking, functional activity limitation, shortness of breath, wheezing, frequency of rescue short-acting beta-2 agonist (SABA) use, and objective airway caliber measured as pre-bronchodilator percent predicted forced expiratory volume in one second (FEV1).

Each item is rated on an equally weighted seven-point categorical scale (scores ranging from 0 to 6), where 0 signifies complete control (no symptoms or impairment) and 6 reflects maximal impairment or severe lack of control. The composite ACQ score is computed as the unweighted arithmetic mean of the completed items, yielding an overall score that ranges from 0 to 6. Validated shortened variants include the ACQ-6 (which excludes the objective spirometric assessment of FEV1) and the ACQ-5 (which excludes both FEV1 and rescue bronchodilator frequency, focusing solely on subjective symptom burden). Across psychometric validation trials, the ACQ exhibits exceptional cross-sectional and longitudinal validity, high internal consistency (Cronbach’s α typically ≥ 0.85), robust test-retest reliability (intraclass correlation coefficient ≥ 0.90), and distinct discriminative capability. An established cut-off score of ≤ 0.75 reflects well-controlled asthma, whereas a score of ≥ 1.50 indicates poorly controlled disease, with an established Minimal Clinically Important Difference (MCID) of 0.5 points.

Keywords

Asthma Control Questionnaire, ACQ, psychometrics, asthma control, Elizabeth Juniper, patient-reported outcome measures, forced expiratory volume, respiratory symptoms, minimally clinically important difference, respiratory health assessment

Authors

The Asthma Control Questionnaire was designed, validated, and published by a distinguished multidisciplinary research consortium based predominantly at McMaster University in Hamilton, Ontario, Canada:

• Elizabeth F. Juniper, MCSP, MSc: Professor Emerita, Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada. Leading authority in respiratory psychometrics and health-related quality of life measurement.
• Paul M. O’Byrne, MB, FRCP(C), FRSC: Professor, Department of Medicine, and Dean and Vice-President, Faculty of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. International expert in asthma pathophysiology and pharmacotherapy.
• Gordon H. Guyatt, MD, MSc, FRCPC: Distinguished Professor, Department of Health Research Methods, Evidence, and Impact (formerly Clinical Epidemiology and Biostatistics), McMaster University. Co-founder of evidence-based medicine and prominent psychometrician.
• Penny J. Ferrie, BSc: Research Coordinator, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
• Donald R. King, MD: Respiratory Physician, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Purpose

The primary clinical and psychometric purpose of the Asthma Control Questionnaire is to provide an objective, standardized, and repeatable index of the degree to which the manifestations of asthma have been eliminated or reduced by therapeutic management or natural disease variation. Clinically, bronchial asthma is characterized by chronic airway inflammation, variable airflow obstruction, and bronchial hyperresponsiveness. International consensus guidelines assert that the therapeutic goal of asthma management is not merely the alleviation of acute bronchoconstriction, but the achievement and maintenance of complete clinical “control,” encompassing both symptom suppression and the minimization of future adverse risk, such as exacerbations and accelerated lung function decline.

Before the introduction of the ACQ, clinicians and clinical trial investigators relied on disjointed, unstandardized assessments. These assessments frequently measured patient symptoms through unvalidated subjective diaries, isolated peak expiratory flow rates, or periodic pulmonary function testing. These fragmented approaches often yielded contradictory appraisals of disease status. The ACQ was systematically engineered to bridge this methodological gap. By synthesizing the cardinal clinical manifestations prioritized by international guidelines—nocturnal awakenings, diurnal morning tightness, exertional dyspnea, wheezing, functional limitation, rescue medication usage, and objective pre-bronchodilator airway caliber—into a single composite score, the ACQ provides a reliable metric that directly informs therapeutic decision-making.

In routine clinical practice, the questionnaire serves as a practical clinical decision aid. Because the metric correlates directly with physiological airway inflammation and risk of future exacerbations, clinicians can determine whether pharmacotherapy (such as inhaled corticosteroids or long-acting bronchodilators) should be titrated up, maintained, or stepped down. In clinical trials, the ACQ functions as a primary or secondary efficacy endpoint, capable of detecting fine-grained longitudinal changes in control in response to novel biological agents, pharmacotherapeutics, or behavioral interventions. Furthermore, the development of the ACQ-5 (symptom-only) and ACQ-6 (symptoms plus rescue medication) variants expanded the instrument’s utility to epidemiological surveys, telehealth environments, and primary care settings where on-site pre-bronchodilator spirometry is logistically unfeasible.

Psychological Construct

The core construct evaluated by the instrument is Asthma Control. In psychometric and respiratory literature, asthma control is distinguished from “asthma severity.” Whereas severity reflects the underlying intrinsic biological intensity of the disease process (judged by the minimum pharmacotherapeutic intensity required to maintain stability), control denotes the adequacy of disease suppression and the immediate functional impact of the illness over a defined timeframe. The ACQ assesses this multidimensional latent construct across seven operational domains, functioning as a single, coherent overarching index.

The specific sub-dimensions measured by the instrument comprise:

• Nocturnal Symptom Burden (Item 1): Sleep disturbance resulting from coughing, wheezing, or chest tightness. Night-time awakenings reflect circadian fluctuations in airway inflammation, parasympathetic tone, and airway resistance, serving as an important clinical warning sign of deteriorating control.
• Morning Symptom Severity (Item 2): The intensity of bronchial constriction upon waking (“morning dipping”). Diurnal variation is a hallmark of unstable asthma, and severe morning symptoms directly impede early daily activities and psychomotor functioning.
• Functional Activity Limitation (Item 3): The degree to which daily occupational, domestic, social, or recreational activities are constrained by respiratory impairment. This dimension quantifies the direct behavioral limitation experienced by the individual.
• Dyspnea Perception (Item 4): The severity of perceived shortness of breath or air hunger. This captures the sensory-perceptual component of asthma exacerbation, which often induces significant psychological distress and anxiety.
• Acoustic Airway Obstruction / Wheezing (Item 5): The proportion of time the patient is aware of continuous, high-pitched musical breathing sounds caused by turbulent airflow through narrowed peripheral airways.
• Reliance on Rescue Pharmacotherapy (Item 6): The average daily frequency of rescue short-acting beta-2 agonist administrations (e.g., albuterol/salbutamol). Frequent rescue inhaler reliance serves as a behavioral and physiological surrogate of breakthrough airway constriction.
• Objective Physiological Impairment (Item 7): Airway obstruction quantified via spirometry as the forced expiratory volume in one second expressed as a percentage of predicted normal value (FEV1 % predicted). This domain anchors patient-reported subjective phenomena to objective pulmonary mechanics.

Extensive psychometric evaluations by Juniper and colleagues demonstrated that while these individual facets represent distinct biological and behavioral expressions of asthma, they align along a single latent continuum of overall disease control.

Theoretical Framework

The conceptual framework underpinning the Asthma Control Questionnaire combines the Biopsychosocial Model with classical psychometric clinimetrics, as formulated by Alvan Feinstein. Feinstein’s clinimetric approach posits that clinical phenomena—such as disease control, dyspnea, and functional burden—are composite medical constructs that cannot always be reduced to pure latent psychometric traits. Instead, they require the systematic integration of subjective perceptual judgments, behavioral adaptations, and biological markers.

The development of the ACQ followed a rigorous clinimetric strategy. Initially, an extensive pool of potential questions reflecting all facets of asthma impairment was administered to 100 respiratory clinicians and clinical trialists who were active contributors to international guidelines. These experts rated the clinical importance of each item. Simultaneously, item characteristics were evaluated in prospective cohorts of patients to verify face, content, and cross-sectional construct validity. The seven final items were selected because they demonstrated both maximum clinical relevance and superior evaluative responsiveness to change.

From a cognitive-behavioral perspective, the ACQ integrates the Common-Sense Model of Self-Regulation (Leventhal et al.), which explores how individuals perceive somatic stimuli, interpret bodily symptoms, and respond with coping actions (such as taking rescue medication or restricting physical activity). Because patients frequently acclimatize to chronic airway obstruction—underreporting symptoms due to unconscious lifestyle modifications or blunted dyspnea perception—the ACQ grounds subjective items within a standardized, short one-week recall interval and couples them with objective spirometric measurement. This structure addresses cognitive recall bias, perceptual desensitization, and subjective over- or under-estimation of physical capacity.

Validity

The ACQ has undergone extensive psychometric validation across clinical, primary care, and multinational randomized controlled trial settings:

• Content and Face Validity: Verified during initial instrument derivation through structured consensus panels involving international asthma specialists and qualitative debriefing with diverse patient cohorts. Items represent all cardinal symptoms specified in the Global Initiative for Asthma management recommendations.
• Construct and Convergent Validity: In the initial validation study by Juniper et al. (1999), cross-sectional correlations between the overall ACQ score and the Asthma Quality of Life Questionnaire (AQLQ) were exceptionally strong (r = -0.76, p < 0.001), indicating that deteriorating asthma control directly impairs health-related quality of life. Furthermore, moderate-to-strong correlations were observed between the ACQ and daily peak expiratory flow (PEF) rates (r = -0.47), rescue bronchodilator use (r = 0.65), and clinical symptom diaries (r = 0.72).
• Discriminant and Known-Groups Validity: The questionnaire reliably discriminates between patients classified by independent clinicians as having well-controlled, partially controlled, or uncontrolled asthma. Receiver Operating Characteristic (ROC) curve analyses demonstrated that an ACQ cutoff score of ≤ 0.75 yields a negative predictive value of > 85% for unstable asthma (confirming well-controlled status), whereas a cutoff of ≥ 1.50 exhibits a positive predictive value of 88% for poorly controlled asthma requiring clinical escalation.
• Evaluative and Longitudinal Responsiveness: Longitudinal studies demonstrate exceptional responsiveness to therapeutic change. When patients experience therapeutic escalation (e.g., initiation of inhaled corticosteroid/long-acting beta-agonist combinations), ACQ scores decrease substantially. The longitudinal correlation between changes in the ACQ and changes in the AQLQ is high (r = -0.68). The Minimal Clinically Important Difference (MCID) was established at 0.50 points on the 0-6 scale. A change in score equal to or exceeding 0.50 represents a clinically meaningful improvement or deterioration in clinical status.

Reliability

The reliability of the ACQ has been confirmed across diverse clinical trials and real-world studies:

• Internal Consistency: Standardized multi-center studies consistently report high internal consistency for the ACQ-7, with Cronbach’s α coefficients ranging from 0.85 to 0.90. The shortened ACQ-6 and ACQ-5 variants demonstrate similarly high internal consistency (α = 0.86 and α = 0.84, respectively), demonstrating strong inter-item relatedness while avoiding redundant item duplication.
• Test-Retest Reliability: In clinically stable asthma cohorts evaluated during repeated visits separated by one to four weeks, the intraclass correlation coefficient (ICC) consistently exceeds 0.90 (ranging from 0.90 to 0.95), reflecting exceptional measurement stability over time in the absence of clinical perturbation.
• Measurement Error and Concordance: Standard error of measurement (SEM) estimates across stable cohorts are low (typically < 0.20 scale units), well below the 0.50 MCID threshold. This low level of measurement noise ensures that observed score changes reflect true biological shifts rather than random questionnaire variability. Furthermore, intraclass correlations between the full 7-item ACQ, the 6-item variant, and the 5-item variant exceed 0.96, confirming measurement concordance across instrument versions.

Factor Analysis

Although the ACQ was developed through a clinimetric paradigm, extensive classical psychometric investigations employing exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) have examined its underlying latent structure:

• Exploratory Factor Analysis: Principal axis factoring and maximum likelihood EFA across both pediatric and adult validation cohorts consistently reveal a dominant unidimensional structure. Analysis of the primary eigenvalues demonstrates that the first unrotated factor accounts for over 50% to 62% of the total variance, with an initial eigenvalue typically exceeding 3.8. Subsequent eigenvalues drop sharply below 0.8, producing an unambiguous scree plot “elbow” that supports a single-factor solution. Factor loadings for all subjective symptom items (items 1 through 5) and rescue bronchodilator use (item 6) are strong, ranging between 0.68 and 0.86.
• Confirmatory Factor Analysis: CFA models testing a single overarching “Asthma Control” latent variable demonstrate good-to-excellent fit indices across various populations. Typical fit statistics include: Comparative Fit Index (CFI) > 0.95, Tucker-Lewis Index (TLI) > 0.94, Root Mean Square Error of Approximation (RMSEA) ≤ 0.06 (90% CI [0.04, 0.08]), and Standardized Root Mean Square Residual (SRMR) ≤ 0.04.
• Behavior of the Spirometric Indicator: In factor analytic models, Item 7 (pre-bronchodilator FEV1 % predicted) consistently displays a lower standardized factor loading (ranging from 0.30 to 0.45) on the latent symptom factor. This finding reflects the recognized clinical discordance between subjective perception of dyspnea and objective physiological airflow limitation. However, structural equation modeling and bifactor analyses demonstrate that retaining FEV1 within the composite model provides an objective physiological anchor that mitigates patient misperception, supporting the clinimetric integrity of the full seven-item measure.

Instrument / Measurement Tool

• Test Type: Patient-Reported Outcome Measure (PROM) combined with clinician-recorded objective spirometry (hybrid clinimetric index).
• Target Population: Adults and adolescents (≥ 12 years of age); an interviewer-administered or modified version is validated for children aged 6–11 years.
• Administration Format: Self-administered paper-and-pencil, electronic tablet/computerized clinical assessment, or validated clinician-administered structured interview.
• Item Count: 7 items in the full ACQ; 6 items in the ACQ-6 (excluding spirometry); 5 items in the ACQ-5 (symptoms only).
• Recall Period: The preceding 7 days (the past week).
• Response Scale: 7-point scale (0 to 6) with unique descriptive anchors for each item (0 = totally controlled/no impairment, 6 = severely uncontrolled/maximum impairment).
• Scoring Rules:
  • The overall ACQ score is the unweighted arithmetic mean of the completed items (sum of item scores divided by the number of completed items).
  • Scores range from 0.0 (completely controlled) to 6.0 (severely uncontrolled).
  • All items are weighted equally.
  • Interpretive Thresholds:
    • ≤ 0.75: Well-controlled asthma.
    • 0.76 – 1.49: Partially controlled / “grey zone” requiring clinical review.
    • ≥ 1.50: Poorly controlled asthma.
  • Minimal Clinically Important Difference (MCID): 0.50 points.

Permissions & Fee and Test Year

The Asthma Control Questionnaire was originally published and copyrighted in 1999 by Elizabeth F. Juniper. The copyright is held by Dr. Elizabeth Juniper through QOL Technologies Ltd. To preserve standardized administration, protect psychometric integrity, and maintain international translation fidelity across more than 100 language adaptations, users must obtain formal licensing permission prior to clinical or investigative implementation.

Academic researchers, clinicians in routine independent clinical practice, and unfunded research studies generally receive access with nominal processing fees or fee waivers upon registration. In contrast, commercial entities, pharmaceutical manufacturers, and industry-sponsored clinical trials are assessed standardized per-subject licensing royalties. Detailed registration and licensing inquiries can be directed to the official clearinghouse at QOL Technologies Ltd.

References

• Juniper, E. F., O’Byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999). Development and validation of a questionnaire to measure asthma control. European Respiratory Journal, 14(4), 902–907. https://doi.org/10.1034/j.1399-3003.1999.14d29.x
• Juniper, E. F., Bousquet, J., Abetz, L., & Bateman, E. D. (2006). Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respiratory Medicine, 100(4), 616–621. https://doi.org/10.1016/j.rmed.2005.08.012
• Juniper, E. F., Svensson, K., Mörk, A. C., & Ståhl, E. (2005). Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respiratory Medicine, 99(5), 553–558. https://doi.org/10.1016/j.rmed.2004.10.008
• Global Initiative for Asthma. (2023). Global Strategy for Asthma Management and Prevention. Available from: https://ginasthma.org/
• Juniper, E. F., Wisniewski, M. E., Cox, F. M., Emmett, A. H., Nielsen, K. E., & O’Byrne, P. M. (2004). Relationship between quality of life and clinical status in asthma: A factor analysis. European Respiratory Journal, 23(2), 287–291. https://doi.org/10.1183/09031936.04.00064204

Items of the Scale